<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Document Security Systems Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/document-security-systems-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SPPI) Spectrum Pharmaceuticals to Continue Cancer Study</title>
		<link>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649</link>
		<comments>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649#comments</comments>
		<pubDate>Fri, 08 Apr 2011 17:19:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics Inc.]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[DMC]]></category>
		<category><![CDATA[Document Security Systems Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals Inc.]]></category>
		<category><![CDATA[SPPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70649</guid>
		<description><![CDATA[Recently, Spectrum Pharmaceuticals Inc. (SPPI) announced that it will continue evaluating its cancer candidate belinostat based on the recommendation of the independent Data Monitoring Committee (DMC). Spectrum Pharma is currently studying belinostat for treating patients suffering from relapsed or refractory peripheral T-Cell lymphoma (PTCL) in a phase II pivotal trial (BELIEF). Spectrum Pharma is evaluating belinostat as a monotherapy in the study. The committee conducted a safety and futility analysis of the interim data from the study before recommending its continuation until 100 evaluable subjects are enrolled. Spectrum Pharma is conducting the study under a Special Protocol Assessment (SPA) with the US Food and Drug Administration (FDA). Spectrum Pharma intends to seek approval of belinostat from the FDA in 2011/2012. We believe that if belinostat is successfully developed and commercialized ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JDSU) JDS Uniphase Launches New Product</title>
		<link>http://www.stockbloghub.com/2011/04/04/jdsu-jds-uniphase-launches-new-product/70427</link>
		<comments>http://www.stockbloghub.com/2011/04/04/jdsu-jds-uniphase-launches-new-product/70427#comments</comments>
		<pubDate>Mon, 04 Apr 2011 13:45:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Communication Equipment]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[DMC]]></category>
		<category><![CDATA[Document Security Systems Inc]]></category>
		<category><![CDATA[Finisar Corporation]]></category>
		<category><![CDATA[FNSR]]></category>
		<category><![CDATA[JDS Uniphase Corporation]]></category>
		<category><![CDATA[JDSU]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70427</guid>
		<description><![CDATA[JDS Uniphase Corporation (JDSU) launched a new product called SAMComplete (Service Activation Methodology) for testing Ethernet service activation. It will belong to the company’s leading J-Complete tools. The new product is a significant addition to the company’s comprehensive product portfolio of testing tools. JDS Uniphase Corporation is the leading provider of communications test and measurement solutions, as well as optical products, to telecom carriers, cable operators, and network equipment manufacturers. The release of the SAMComplete testing instrument will allow multiple activations of Ethernet-based services, thus offering faster and high-quality mobile video services along with other advanced services. The newly-launched tool is quite easy to operate as compared to its other testing tools. J-Complete’s product portfolio comprises many such testing tools that are available with the T-BERD®/MTS 6000A Multi Services Application Module ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/04/jdsu-jds-uniphase-launches-new-product/70427/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Terminates Letairis Phase III Trial</title>
		<link>http://www.stockbloghub.com/2010/12/24/gild-gilead-sciences-terminates-letairis-phase-iii-trial/63567</link>
		<comments>http://www.stockbloghub.com/2010/12/24/gild-gilead-sciences-terminates-letairis-phase-iii-trial/63567#comments</comments>
		<pubDate>Fri, 24 Dec 2010 20:10:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMC]]></category>
		<category><![CDATA[Document Security Systems Inc]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[United Therapeutics Corporation]]></category>
		<category><![CDATA[UTHR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63567</guid>
		<description><![CDATA[Gilead Sciences Inc.(GILD) recently announced that it will terminate its phase III trial (ARTEMIS-IPF) studying Letairis (ambrisentan) for the treatment of idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. The study’s Data Monitoring Committee (DMC) had conducted an interim analysis of the efficacy and safety data of the trial. The data was also reviewed by Gilead. It did not show any treatment benefit in the patients receiving Letairis. Gilead is currently conducting a thorough analysis of the data and will present the results of the analysis once they are available. Letairis, currently marketed for the treatment of pulmonary arterial hypertension (PAH), competes with drugs like Actelion Pharmaceuticals’  Tracleer (bosentan) United Therapeutics’ (UTHR) Tyvaso and Adcirca and Pfizer’s (PFE) Revatio. Letairis is not the key revenue generator for Gilead and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/24/gild-gilead-sciences-terminates-letairis-phase-iii-trial/63567/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer&#8217;s Developmental Candidate Sutent Disappoints Again</title>
		<link>http://www.stockbloghub.com/2010/08/24/pfe-pfizers-developmental-candidate-sutent-disappoints-again/49221</link>
		<comments>http://www.stockbloghub.com/2010/08/24/pfe-pfizers-developmental-candidate-sutent-disappoints-again/49221#comments</comments>
		<pubDate>Tue, 24 Aug 2010 23:14:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMC]]></category>
		<category><![CDATA[Document Security Systems Inc]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49221</guid>
		<description><![CDATA[Pfizer Inc.’s (PFE) Sutent faced yet another development setback when the company announced that the candidate failed to achieve its primary endpoint in a late-stage study (SUN 1087) that was being conducted in patients suffering from non small-cell lung cancer (NSCLC). Results showed that Sutent, when used in combination with Roche’s (RHHBY) Tarceva (erlotinib), failed to demonstrate a statistically significant improvement in overall survival compared to Tarceva alone. However, Sutent showed a statistically significant improvement in progression-free survival, the secondary endpoint of the study. Pfizer reported that no new or unforeseen adverse events occurred in the study. The company intends to further analyze the results which will be presented at the European Society for Medical Oncology (ESMO) Congress in October 2010. Based on a detailed analysis, Pfizer could opt to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/24/pfe-pfizers-developmental-candidate-sutent-disappoints-again/49221/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

